You are here: » News » Newsdetails: Uncertainty for Gene Therapy


Uncertainty for Gene Therapy

September 14, 2017

Uncertainty for gene therapy following withdrawal from market of Europe’s first gene therapeutic

Dutch biotechnology company uniQure B.V., (NASDAQ:QURE), Amsterdam, The Netherlands, has announced that it will not pursue the renewal of its Glybera (alipogene tiparvovec) marketing authorization in Europe, scheduled to expire on October 25, 2017.

Missing some information on

* mandatory field